Compare Ascendis Pharma A/S (ASND) vs Vale SA (VALE) Price & Performance
Price performance
Price movement over the last 24 hours
Key statistics
Key statistics
Ascendis Pharma A/S vs Vale SA — how do they compare? Ascendis Pharma A/S trades at $270.99 (market cap $17.74B), while Vale SA trades at $14.24 (market cap $60.94B). The key difference: Vale SA is far larger — about 3.4× Ascendis Pharma A/S's market cap, and Vale SA pays a 8.7% dividend while Ascendis Pharma A/S pays none. Which is the better fit depends on your goals.
| ASND | VALE | |
|---|---|---|
Market Cap | $17.74B | $60.94B |
Sector | Health | Basic Materials |
52-Week High | $277.18 | $17.82 |
52-Week Low | $163.32 | $9.53 |
Enterprise Value | $18.11B | $77.86B |
Dividend Yield | — | 8.7% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Ascendis Pharma (ASND) trades at $270.45, down 1.81% on the day, with a bullish technical outlook supported by moving averages and positive analyst sentiment. The company reported Q1 2026 revenue of $241 million (converted from €197 million for YORVIPATH and €44 million for SKYTROFA, Q1 2026 earnings report May 7, 2026) and beat EPS expectations, while recent news highlights clinical progress in achondroplasia and hypoparathyroidism treatments. Valuation ratios are elevated with a P/E of 31.38 and P/S of 16.94, reflecting growth expectations.
The outlook is positive due to strong revenue growth, multiple product launches, and a 92% analyst buy rating with a $321.17 price target. Key risks include high debt levels, persistent net losses despite improving margins, and reliance on successful commercialization of new therapies. The stock's upside depends on execution of growth strategy and achieving profitability.
VALE trades at $14.46, up 1.69% with mixed earnings performance including a Q3 2025 beat but recent misses. Technical indicators show bearish momentum with oversold RSI signals. The company maintains solid cash flow generation ($2.42B net in 2025) despite declining profit margins from 42.85% in 2022 to 6.12% in 2025. Recent news highlights $2.56B decarbonization investments and governance developments.
VALE presents a cautious opportunity with analyst consensus at $17.50 (21% upside) but faces margin compression and debt increases. The stock's value proposition hinges on commodity price recovery and successful execution of efficiency initiatives amid competitive and macroeconomic pressures.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Ascendis Pharma A/S
Ascendis Pharma A/S is a biopharmaceutical company. It develops prodrug therapies with profiles to address large markets with significant unmet medical needs with its Transcon technology. The firm's product pipeline includes Transcon growth hormone, Transconpeptides, Transcon PTH, Transcon CNP, and others. It operates mainly in North America, Germany, China, and Denmark and derives the majority of its revenue from China.
Read more on ASND →About Vale SA
Vale is the world's largest iron ore miner and one of the largest diversified miners, along with BHP and Rio Tinto. Earnings are dominated by the bulk materials division, primarily iron ore and iron ore pellets, with minor contributions from iron ore proxies, including manganese and coal. The base metals division is much smaller, primarily consisting of nickel mines and smelters with a small contribution from copper.
Read more on VALE →
